Gain Therapeutics (GANX) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Gain Therapeutics (GANX) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.64% |
| Mar 31, 2026 | -1,589.58% |
| Dec 31, 2025 | 107.13% |
| Sep 30, 2025 | 9.04% |
| Jun 30, 2025 | -28.23% |
| Mar 31, 2025 | -20.21% |
| Dec 31, 2024 | 15.99% |
| Sep 30, 2024 | 44.91% |
| Jun 30, 2024 | -102.86% |
| Mar 31, 2024 | 19.93% |
| Dec 31, 2023 | -6.26% |
| Sep 30, 2023 | 38.63% |
| Jun 30, 2023 | -49.65% |
| Mar 31, 2023 | -140.56% |
| Dec 31, 2022 | 377.90% |
| Sep 30, 2022 | 10.37% |
| Jun 30, 2022 | -55.39% |
| Mar 31, 2022 | -1.64% |
| Dec 31, 2021 | 30.96% |
| Sep 30, 2021 | -31.12% |